Enzyme

Enzyme is a San Francisco, California-based software company that develops quality management system platforms to automate regulatory approval and compliance processes for life sciences organizations. The enterprise primarily serves corporate clients and institutions operating within the medical device, digital health, and biopharmaceutical sectors by digitizing their product development and auditing lifecycles. Operating with a workforce of 32 employees, the organization provides digital infrastructure designed to navigate complex healthcare regulatory frameworks and accelerate market access for new medical technologies. The platform replaces manual documentation with integrated software tools that track design controls, risk management, and post-market surveillance data across the global healthcare industry. Backed by venture capital investors including Y Combinator, Refactor Capital, and Data Collective (DCVC), the firm supports healthcare innovators through rigorous compliance milestones. Enzyme was founded in 2017 by Jared Seehafer and Jacob Graham.

High-Level Overview

Enzyme is a software company that automates regulatory approval and compliance processes for life science companies, including those in medical devices, biopharma, digital health, and diagnostics. Its core product is an online Quality Management System (QMS) platform that simplifies and streamlines the complex workflows involved in FDA compliance and regulatory submissions. By replacing cumbersome documents and spreadsheets with a modern, integrated system, Enzyme helps development teams reduce time to market and focus on delivering clinical value to patients. The platform serves startups to established companies, supporting regulatory needs from premarket to postmarket stages. Enzyme has demonstrated growth momentum, with adoption by notable companies such as PathAI and Biomeme, and has attracted investment from firms like Refactor Capital and Data Collective[1][2][4][5].

Origin Story

Enzyme was founded in 2017 by Jared Seehafer and Jacob Graham, industry veterans with over a decade of experience in regulatory and quality systems within biopharma and medical device sectors. Frustrated by the inefficiencies and fragmentation of existing QMS tools—often requiring multiple software solutions and extensive manual work—they created Enzyme to unify and simplify regulatory compliance workflows. Their deep regulatory expertise and firsthand knowledge of the challenges companies face in preparing FDA submissions inspired the development of a user-friendly platform that generates FDA-ready documentation with ease. Early traction came through participation in Y Combinator’s Summer 2017 batch and securing clients in the medical device and diagnostics space, which validated the product-market fit[1][2][4].

Core Differentiators

• Product Differentiators: Enzyme offers a modern, integrated QMS platform that replaces tens of thousands of documents and spreadsheets with a streamlined, digital system tailored for life science regulatory compliance.
• Developer Experience: Designed by quality and regulatory professionals, the platform adapts to users’ workflows rather than forcing rigid processes, enhancing usability and efficiency.
• Speed and Ease of Use: Enables rapid generation of internal reports and FDA-ready submissions, significantly reducing time and resource expenditure in regulatory processes.
• Consulting and Support: Unique among QMS vendors, Enzyme provides regulatory and quality consulting services, including audit preparation, submission writing, and FDA representation, supporting clients from product inception through approval.
• Community Ecosystem: Enzyme’s team brings over 50 years of combined medical device industry experience, fostering trust and deep domain expertise for clients[1][2][3][4].

Role in the Broader Tech Landscape

Enzyme rides the growing trend of digital transformation in life sciences, where regulatory compliance is a critical but costly and complex barrier to innovation. As regulatory agencies like the FDA streamline oversight of digital health and medical devices, companies increasingly need scalable, automated compliance solutions. Enzyme’s timing is advantageous, addressing a market demand for tools that reduce regulatory overhead and accelerate product commercialization. By modernizing quality management systems, Enzyme influences the broader ecosystem by enabling faster innovation cycles and lowering the risk associated with regulatory submissions, thus fostering a more dynamic life science startup environment[1][2][5].

Quick Take & Future Outlook

Following its acquisition by Greenlight Guru in 2025, Enzyme’s technology and customer base are positioned for accelerated growth and integration into a larger platform focused on MedTech and life sciences innovation. The consolidation reflects a broader industry trend toward unified, comprehensive compliance solutions. Future trends shaping Enzyme’s journey include increasing regulatory complexity, the rise of digital health products, and the demand for faster time-to-market without compromising patient safety. Enzyme’s influence is likely to expand as it continues to empower life science companies to innovate efficiently while maintaining rigorous compliance, ultimately driving better patient outcomes and transforming regulatory workflows[8].